2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|October 26, 2017
UBM Announces BioLive Event
Author(s)Pharmaceutical Technology Editors
The new BioLive event, which will be a global hub for biopharmaceutical manufacturing, will launch alongside CPhI Worldwide 2018 in Madrid.
Advertisement
On Oct. 26, 2017, UBM announced a new biopharma event, BioLive, that will launch alongside CPhI Worldwide 2018 in Madrid from Oct. 9–11, 2018. The show will offer a mixture of science and technology content through presentations and conferences alongside business development and partnering programs.
The new event, which will focus on bioprocessing and manufacturing, will serve as a global hub for upstream and downstream processing and will connect biotechnology firms, Big Pharma, and service providers working in early stage development through commercial manufacturing, as well as regulatory services. BioLive will help Big Pharma companies to assess the specific niche services they need, such as analytics and testing. The event will also empower small- and medium-sized bio-innovators who want to feed new therapies into the development pipelines of larger companies. Bio-innovators will be able to look for the external partners they need to push forward their drug development and commercialization programs.
“It’s a hugely exciting time for the bio industry globally, and we expect rapid growth in what is now a maturing supply chain. Independent research showed a dissatisfaction amongst existing options, and we have identified that we can provide broader depth in bio manufacturing and processing, whilst capitalizing on our collective portfolio strength to bring additional value by combining the small- and large-molecule worlds together with contract services,” commented Rutger Oudejans, brand director at UBM, in a press release. He added, “It is firstly to provide an ecosystem to bring together the bio development and manufacturing sectors. But it also enables companies and professionals involved across the full pharma value chain of both small- and large-molecule to learn from each other and evolve new strategies to overcome the challenges in bio processing and manufacturing.”
UBM is the parent company of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
Advertisement
Related to this article
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement